Mark Worthington is CLO & CCO at Athira Pharma, Inc. (ATHA). They have made 7 open-market trades across 2 companies since 2022, most recently 2026-03-04.
CIK 0001861464
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 7 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ATHA | 14,854 | $100K |
| LONA | 18,376 | — |
| Total | $100K |
Shares reported on the most recent Form 4, priced at the 2026-03-05 close. 1 holding could not be priced and is excluded from the total.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| LONA | SELL | 2026-03-04 | 2026-03-05 | $5.37 | $7K | N/A | N/A | N/A |
| ATHA | SELL | 2026-01-02 | 2026-01-05 | $6.88 | $6K | N/A | N/A | N/A |
| ATHA | SELL | 2025-07-01 | 2025-07-02 | $0.29 | $2K | +34.3% | +25.5% | +40.3% |
| ATHA | SELL | 2025-01-02 | 2025-01-03 | $0.56 | $5K | -10.6% | -15.8% | -56.2% |
| ATHA | SELL | 2024-09-05 | 2024-09-05 | $0.57 | $1K | -12.5% | -22.7% | +12.1% |
| ATHA | SELL | 2024-01-05 | 2024-02-16 | $2.91 | $7K | +4.6% | -32.3% | -26.4% |
| ATHA | SELL | 2022-06-23 | 2022-06-24 | $2.69 | $7K | +35.4% | +18.6% | +19.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.